Exact Mass: 420.2220032
Exact Mass Matches: 420.2220032
Found 186 metabolites which its exact mass value is equals to given mass value 420.2220032
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Levocabastine
C26H29FN2O2 (420.22129459999996)
Levocabastine is only found in individuals that have used or taken this drug. It is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.Levocabastine is a potent, selective histamine H1-receptor antagonist. It works by competing with histamine for H1-receptor sites on effector cells. It thereby prevents, but does not reverse, responses mediated by histamine alone. Levocabastine does not block histamine release but, rather, prevents histamine binding and activity. Levocabastine also binds neurotensin 2 receptors and serves as a neurotensin agonist. This can induce some degree of analgesia. R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AC - Antiallergic agents, excl. corticosteroids D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Armillane
Armillane is found in mushrooms. Armillane is a metabolite of Armillaria mellea (honey mushroom Metabolite of Armillaria mellea (honey mushroom). Armillane is found in mushrooms.
(8alpha,10alpha,13alpha,17beta)-17-[(4-Hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
Cabastine
C26H29FN2O2 (420.22129459999996)
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
DGAT-1 inhibitor 2
DGAT-1 inhibitor 2 is an effective inhibitor of DGAT-1;antiobesity agents. IC50 value: Target: DGAT-1 Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) is one of two known DGAT enzymes that catalyze the final step in triglyceride synthesis. Findings from genetically modified mice as well as pharmacological studies suggest that inhibition of DGAT1 is a promising strategy for the treatment of obesity and type 2 diabetes.
Hexoprenaline
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents
8-(3-(1-((3-Fluorophenyl)methyl)-4-piperidinyl)-1-oxopropyl)-1,2,5,6-tetrahydro-4h-pyrrolo(3,2,1-ij)quinolin-4-one
C26H29FN2O2 (420.22129459999996)
8-[3-[1-[(3-Fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline-4-one
C26H29FN2O2 (420.22129459999996)
Trichoverrol A
D009676 - Noxae > D011042 - Poisons > D014255 - Trichothecenes D009676 - Noxae > D011042 - Poisons > D009183 - Mycotoxins CONFIDENCE isolated standard
8beta-Acetoxy-3beta-angeloyloxy-5alpha-hydroxycostic acid methyl ester
Deacetylpseudolaric acid A 2,3-dihydroxypropyl ester
[4beta(2Z,4E,6S,7S)]- 12,13-Epoxytrichothec-9-ene-4,16-diol 4-(6,7-dihydroxy-2,4-octadienoate)
Trichoverrol B
[4beta(2Z,4E,6S,7R)]-12,13-Epoxytrichothec-9-ene-4,16-diol 4-(6,7-dihydroxy-2,4-octadienoate)
(5R,9aS,9bS)-9b-Hydroxy-6,6,9a-trimethyl-1-oxo-1,3,5,5a,6,7,8,9,9a,9b-decahydronaphtho[1,2-c]furan-5-yl (2E,4E)-6,7-dihydroxy-2,4-octadienoate
4-Benzyl-2-({4-[5-(trifluoromethyl)-2-pyridinyl]piperazino}methyl)
3beta,5,12beta,14-Tetrahydroxy-19-oxo-5beta,14beta-card-20(22)-enolid|3beta,5,12beta,14-tetrahydroxy-19-oxo-5beta,14beta-card-20(22)-enolide|antiarigenin
Armillane
3-oxo-14,3-oxy-3(4->18)-abeo-brevia-1,4(18),12,2,4-pentaene 1,5-lactone|brevione C
17alpha-strophadogenin|5beta,14beta,16beta-trihydroxy-19-oxo-17alpha-card-20(22)-enolide
rel-(7S,8R,1R,3S,4S,5S)-Delta8-4-hydroxy-3,4,5,3,5-pentamethoxy-1,2,3,4,5,6-hexahydro-2-oxo-7.3,8.1-neolignan
3-hydroxy-24-methyl-25-oxo-hexacosa-5,7,9,11,13,15,17,19,21,23-decaenoic acid|laetiporic acid
9alpha-hydroxy-6beta-(6,6-dimethoxyhex-2E,4E-dienoyloxy)-5alpha-drim-7-en-11,12-olide|ustusolate D
9beta-hydroxy-14-isobutyryloxyalbicolide-15-O-isobutyrate
20(R)-15alpha-acetoxy-6beta-hydroxy-20-methoxy-6,20alpha-epoxy-6,7-seco-1alpha,7-olide-ent-kaur-16-ene|20(S)-15alpha-acetoxy-6beta -hydroxy-20-methoxy-6,20alpha-epoxy-6,7-seco-ent-kanr-16-en-1alpha,7-olide|isodonhenrin B|isorosthin C
1alpha-acetoxy-5alpha,7beta-dihydroxy-12alpha-methoxycassa-14(17),13(15)-dien-16,12-olide|caesalpin G
Caesalpine A
(7R,8S,2R,3R,4R,5S)-Delta(8)-2,4-dihydroxy-3,4,5,3,5-pentamethoxy-2,3,4,5-tetrahydro-2-oxo-7.3,8.5-neolignan|nectamazin C
1alpha-Hydroxy-6-O-isobutyryl-3beta-isobutyryloxysteiractinolid
[(5R,9aS,9bS)-9b-hydroxy-6,6,9a-trimethyl-1-oxo-3,5,5a,7,8,9-hexahydrobenzo[e][2]benzofuran-5-yl] (2E,4E)-6,7-dihydroxyocta-2,4-dienoate
6-[(2E,6E)-4,5-dihydroxy-4,6-dimethyl-7-(1,2,4-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-4-yl)hepta-2,6-dien-2-yl]-4-methoxy-5-methylpyran-2-one
C23H32O7_(5R,9aS,9bS)-9b-Hydroxy-6,6,9a-trimethyl-1-oxo-1,3,5,5a,6,7,8,9,9a,9b-decahydronaphtho[1,2-c]furan-5-yl (2E,4E)-6,7-dihydroxy-2,4-octadienoate
C23H32O7_1-Phenanthrenecarboxylic acid, 10-(acetyloxy)-1,2,3,4,4a,9,10,10a-octahydro-4,5,9-trihydroxy-1,4a-dimethyl-7-(1-methylethyl)-, methyl ester
methyl 10-acetyloxy-4,5,9-trihydroxy-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
6-[(2E,6E)-4,5-dihydroxy-4,6-dimethyl-7-(1,2,4-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-4-yl)hepta-2,6-dien-2-yl]-4-methoxy-5-methylpyran-2-one [IIN-based: Match]
6-[(2E,6E)-4,5-dihydroxy-4,6-dimethyl-7-(1,2,4-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-4-yl)hepta-2,6-dien-2-yl]-4-methoxy-5-methylpyran-2-one [IIN-based on: CCMSLIB00000848593]
methyl 10-acetyloxy-4,5,9-trihydroxy-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate_major
Ala His Pro Pro
Ala Pro His Pro
Ala Pro Pro His
His Ala Pro Pro
His Pro Ala Pro
His Pro Pro Ala
Ile Ser Thr Thr
Ile Thr Ser Thr
Ile Thr Thr Ser
Leu Ser Thr Thr
Leu Thr Ser Thr
Leu Thr Thr Ser
Pro Ala His Pro
Pro Ala Pro His
Pro His Ala Pro
Pro His Pro Ala
Pro Pro Ala His
Pro Pro His Ala
Ser Ile Thr Thr
Ser Leu Thr Thr
Ser Thr Ile Thr
Ser Thr Leu Thr
Ser Thr Thr Ile
Ser Thr Thr Leu
Thr Ile Ser Thr
Thr Ile Thr Ser
Thr Leu Ser Thr
Thr Leu Thr Ser
Thr Ser Ile Thr
Thr Ser Leu Thr
Thr Ser Thr Ile
Thr Ser Thr Leu
Thr Thr Ile Ser
Thr Thr Leu Ser
Thr Thr Ser Ile
Thr Thr Ser Leu
Thr Thr Thr Val
Thr Thr Val Thr
Thr Val Thr Thr
Val Thr Thr Thr
Cabastine
C26H29FN2O2 (420.22129459999996)
R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AC - Antiallergic agents, excl. corticosteroids D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Brifentanil
C20H29FN6O3 (420.22850559999995)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent
sodium 2-[2-[2-(dodecyloxy)ethoxy]ethoxy]ethyl sulphate
C18H37NaO7S (420.21575720000004)
1-BOC-4-(2-CBZ-AMINO-2-METHOXYCARBONYL-ETHYL)PIPERIDINE
13-cis-12-(3-Carboxyphenyl)retinoic acid
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
(8alpha,10alpha,13alpha,17beta)-17-[(4-Hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
Methyl 6-(acetyloxy)-1,7,11-trihydroxyabieta-8(14),9(11),12-trien-18-oate
Hexoprenaline
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents
tert-butyl 4-[5-(4-phenoxyphenyl)-1H-pyrazol-3-yl]piperazine-1-carboxylate
[(5R,9aS,9bS)-9b-hydroxy-6,6,9a-trimethyl-1-oxo-3,5,5a,7,8,9-hexahydrobenzo[e][2]benzofuran-5-yl] (2E,4E)-6,7-dihydroxyocta-2,4-dienoate
1-[1-[1-(1,3-Benzodioxol-5-ylmethyl)-5-tetrazolyl]-2-methylpropyl]-4-phenylpiperazine
6-[(2E,6E)-4,5-Dihydroxy-4,6-dimethyl-7-(2,4,5-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-2-yl)hepta-2,6-dien-2-yl]-4-methoxy-5-methylpyran-2-one
2-[(2S,3R,6S)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2S,3S,6R)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
(4S,7S)-4-[(4-methoxyphenyl)methyl]-7-(phenylmethyl)-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(5S,8S)-8-[(4-methoxyphenyl)methyl]-5-(phenylmethyl)-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
(5S,8R)-8-[(4-methoxyphenyl)methyl]-5-(phenylmethyl)-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
1-[(1R)-1-(hydroxymethyl)-7-methoxy-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-(3-pyridinyl)ethanone
N-(2-hydroxyphenyl)-N-[(E)-(1-methylindol-3-yl)methylideneamino]octanediamide
2-[(2S,3R,6R)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,3S,6S)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,3S,6R)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,3R,6S)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2S,3S,6S)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,3R,6R)-3-[[(4-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
(4R,7S)-4-[(4-methoxyphenyl)methyl]-7-(phenylmethyl)-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(5R,8S)-8-[(4-methoxyphenyl)methyl]-5-(phenylmethyl)-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
(5R,8R)-8-[(4-methoxyphenyl)methyl]-5-(phenylmethyl)-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
1,7-Bis(3,5-diethyl-4-hydroxyphenyl)hepta-1,6-diene-3,5-dione
(2-hydroxy-3-phosphonooxypropyl) (9Z,12Z)-heptadeca-9,12-dienoate
(8xi,9xi,14xi,17xi)-3,5,14,19-Tetrahydroxy-19-oxocard-20(22)-enolide
2-hydroxy-1,3-dimethoxy-6-methyl-5-(prop-2-en-1-yl)-7-(3,4,5-trimethoxyphenyl)bicyclo[3.2.1]octan-8-one
methyl (1s,2s,3s,6r,7s,10r,11r,12r)-2-[5-(2h-1,3-benzodioxol-5-yl)pentyl]tetracyclo[8.2.1.0³,¹².0⁶,¹¹]trideca-4,8-diene-7-carboxylate
(1r,2r,3as,3br,5as,7r,8r,9ar,9bs,11ar)-2,3a,7,8-tetrahydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde
methyl (1s,2s,3r,6r,7r,10s,11s,12s)-2-[5-(2h-1,3-benzodioxol-5-yl)pentyl]tetracyclo[8.2.1.0³,¹².0⁶,¹¹]trideca-4,8-diene-7-carboxylate
11'-(acetyloxy)-1',5'-dimethyl-8'-oxaspiro[oxirane-2,12'-tricyclo[7.2.1.0²,⁷]dodecan]-5'-en-2'-ylmethyl 5-hydroxy-3-methylpent-2-enoate
2,4,8-trimethyl (1r,2s,3r,4r,6r,8r,9r,12r)-6-hydroxy-4-methyl-13-methylidenetetracyclo[10.2.1.0¹,⁹.0³,⁸]pentadecane-2,4,8-tricarboxylate
5-methoxy-2-methyl-4-[(1r,6r)-4-(4-methylpent-3-en-1-yl)-6-phenylcyclohex-3-ene-1-carbonyl]benzene-1,3-diol
2a,4-dihydroxy-3-(hydroxymethyl)-6,6,7b-trimethyl-octahydrocyclobuta[e]inden-2-yl 2,4-dihydroxy-6-methylbenzoate
(5-hydroxy-3-methylidene-6-{[(2-methylpropanoyl)oxy]methyl}-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-10-yl)methyl 2-methylpropanoate
(5e,7e,9e,11e,13e,15e,17e,19z,21e,23e)-3-hydroxy-24-methyl-25-oxohexacosa-5,7,9,11,13,15,17,19,21,23-decaenoic acid
(2r)-2,3-dihydroxypropyl (2e,4e)-5-[(1r,7s,8r,9r)-7-hydroxy-4,9-dimethyl-11-oxo-10-oxatricyclo[6.3.2.0¹,⁷]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate
(1r,3as,3br,5as,7s,9as,9bs,11r,11as)-3a,5a,7,11-tetrahydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
3,4a,6',7,7',11a-hexamethyl-5,6,6a,11b-tetrahydro-1h,3'h-spiro[cyclohepta[a]naphthalene-4,2'-furo[3,2-c]pyran]-4',9-dione
5-[(2s,3s)-3-[(3,4-dimethoxyphenyl)methyl]-4-methoxy-2-(methoxymethyl)butyl]-3-methoxybenzene-1,2-diol
4a-hydroxy-4,4,11b-trimethyl-7-methylidene-1h,2h,3h,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-5-yl benzoate
n-{1-[6-(ethylsulfanyl)-3,4,5-trihydroxyoxan-2-yl]-2-hydroxypropyl}-1-methyl-4-propylpyrrolidine-2-carboximidic acid
C19H36N2O6S (420.22939560000003)